MOUNT TAM BIOTECHNOLOGIES
Mount Tam Biotechnologies was established in 2014 to develop, optimize and bring to market novel pharmaceutical products to improve the health and well-being of patients suffering from a range of serious disease states where there is significant unmet need. Our most advanced compound is being developed to treat systemic lupus erythematosus (SLE).
Mount Tam Biotechnologies is a specialty biopharmaceutical company focused on the discovery and development of novel mTOR modulators to address serious unmet need across a range of therapeutic areas. With a strong management team that brings the experience and expertise necessary to move novel compounds through discovery and through the clinical trials, Mount Tam is positioned to deliver on our mission of providing leadership in the field of mTOR modulators.
Combining our research collaboration with the world-renowned Buck Institute for Research on Aging, our proprietary discovery platform and our lead compound targeting systemic lupus erythematosus (SLE), TAM-01, Mount Tam brings a unique focus and value proposition to the biotechnology space.
Mount Tam’s drug discovery platform is based on our proprietary approach to development of novel ‘rapalogs’ (rapamycin-like molecules) that deliver greater mTORC1 selectivity vs. currently marketed compounds. mTORC1 is one of the complexes formed by mTOR, a master regulator of cell growth and metabolism.
mTORC1 activity has been shown to increase both with aging and in a range of disease states that can have a severe impact on both length and quality of life. At Mount Tam, we are focused on bringing to bear our unique combination of expertise in the science of mTOR modulation, medicinal chemistry and pre-clinical and clinical development to address serious unmet need. We do this by discovering and bringing into the clinic novel mTORC1 inhibitors that have the potential to address a broad range of diseases including autoimmune disease, neurodegenerative disease, and a number of rare genetic diseases where mTORC1 activity is known to be increased.
Our platform allows us to rapidly engineer new compounds with superior mTORC1 selectivity and to rapidly screen them for efficacy across a range of disease states.
AELAN CELL TECHNOLOGIES
Aelan Cell Technologies is engaged in the research, discovery, development and commercialization of innovative biomedical technologies for the advancement of human health and longevity.
Emporia Software is building the world's first direct Music Search Engine that will directly search in real-time, without metadata, entire music catalogues in all their musical dimensions.
Noisecastle III is a music production house that has exclusively licensed the entertainment rights to composer, producer and song writer Scott Bruzenak. One of Scott's highlights includes producing and co-writing Daya's double-platinum singles "Hide Away" and “Sit Still, Look Pretty”.
POMPEII SUSTAINABLE PRESERVATION PROEJECT
US Equity Holdings is a Strategic Partner to the Pompeii Sustainable Preservation Project, a cooperation of leading research institutions in Europe that are working to protect and preserve the UNESCO World Heritage Site.
PV TECH GROUP
PV Tech Group provides a comprehensive range of services to photovoltaic manufacturers including full-scale integration of photovoltaic manufacturing facilities, strategic planning, technical evaluation, process optimization and project management.
Rokio, Inc. is the owner of the Direct Learning machine learning platform. Developed in an incubator funded by Silicon Valley visionary, Carl Berg.
Sail Maui is Maui's fastest high performance sailing company. With over 21 years of business experience, Sail Maui has become Maui's premier catamaran company, hosting thousands of trips across Hawaii.
Walter Afanasieff is a multi-Grammy Award winning record producer and songwriter. Walter won his first Grammy for producing "My Heart Will Go On" by Celine Dion, which became the theme song to the 1997 film Titanic.